Orthocell releases March quarterly results

What happened: Orthocell Ltd (ASX:OCC) is set to release its March quarterly results on April 20, 2026, and host an investor webinar the same day. The webinar will cover its quarterly results and provide an operational update, including progress on the US rollout of Remplir. Notably, Orthocell has recently achieved first commercial sales of Remplir™ in Canada, marking the start of revenue generation in the country’s estimated US$75 million nerve repair market.

Market impact: This narrative impacts the medical device sector, particularly companies operating in the nerve repair market. Orthocell's quarterly results and operational update will provide insights into its growth trajectory, potentially driving investment decisions. The first Canadian sales of Remplir™ signal market acceptance and could encourage further adoption, benefiting Orthocell's revenue growth and valuation.

What to watch next: Investors should closely monitor Orthocell's March quarterly results and the April 20 webinar for updates on Remplir's US rollout and potential revenue guidance. Additionally, the market will watch for further commercial sales and regulatory updates from Orthocell, as these could drive future growth and valuation.